Medline (MDLN)
Medline (MDLN) is covered by Stockchase stock experts. Read their latest opinions, ratings and top picks below.
Financials 
Technical Analysis 
It went public today. Through the first 9 months of 2025: 9.8% net sales growth and 12.9% adjusted EBITDA margin. Boasts sold revenue growth in recent years and has a decent, not great, balance sheet. Those buying shares today will have little voting power while existing shareholders will hold 80% of the vote. Today, shares closed +41% above the offers price, so the share price is rich. Trades at roughly 45x PE, which is high for low double-digit growth. Likes this, but buy at $29-30.
- «
- ‹
- 1
- ›
- »
Popular Articles
Medline (MDLN) Frequently Asked Questions
What is Medline stock symbol?
Medline is a OTC stock, trading under the symbol MDLN (previously MDLN-Q on Stockchase) on the undefined (undefined). It is usually referred to as or MDLN
Is Medline a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on MDLN (previously MDLN-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Medline .
Is Medline a good investment or a top pick?
Medline was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Medline .
Why is Medline stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Medline .
Is Medline worth watching?
Medline is covered by Stockchase experts and is worth watching.
Is up 39.4% since its IPO last month. Though off its highs, it looks healthy and is better than many IPOs last year.